世界の遺伝子治療市場予測（～2020）...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Gene Therapy – An Introduction
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.2 Non Viral Vectors
4. Industry Overview
4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 Stringent Regulatory Laws & Safety Concerns
4.2.2 Pitfalls in Current Technique
4.2.3 High Cost of the Gene Therapy Drugs
4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends
4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in R&D Activities
5. Clinical Trial Assessment & Pipeline Analysis
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis
6. Gene Therapy Market – Regulatory Landscape & Reimbursement Scenario
6.1 Regulatory Landscape
6.1.1 US
6.1.2 Canada
6.1.3 Europe
6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market
7. Marketed Gene Therapies
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine
8. Global Gene Therapy Market
9. Gene Therapy Market by Application
9.1 Oncology
9.1.1 Clinical Trials
9.1.1 Prevalence
9.1.3 Market Outlook
9.2 Cardiovascular Diseases
9.2.1 Clinical Trials
9.2.2 Prevalence
9.2.3 Market Outlook
9.3 Infectious Diseases
9.3.1 Clinical Trials
9.3.2 Prevalence
9.3.3 Market Outlook
9.4 Neurological Diseases
9.4.1 Clinical Trials
9.4.2 Prevalence
9.4.3 Market Outlook
9.5 Genetic Diseases
9.5.1 Clinical Trials
9.5.2 Prevalence
9.5.3 Market Outlook
9.6 Others
9.6.1 Clinical Trials
9.6.2 Prevalence
9.6.3 Market Outlook
10. Global Gene Therapy Market Size by Geography
10.1 North America
10.2 Europe
10.3 Asia
10.4 Rest of the World (RoW)
11. Competitive Landscape
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding & Investments
11.2 Companies Progress in Gene Therapy In 2015
12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)
12.1 Spark Therapeutics, LLC
12.2 ViroMed Co. Ltd. dba VM BioPharma
12.3 Advantagene Inc.
12.4 Bluebird Bio
12.5 Sanofi
12.6 Vical Inc.
12.7 Oxford BioMedica Plc
12.8 Genethon
12.9 uniQure N.V.
12.10 Human Stem Cells Institute
12.11 Shanghai Sunway Biotech Co. Ltd.
12.12 Sibiono GeneTech Co. Ltd.

List of Figures:

Figure 4-1: Global – Major Venture Capitalist Investments in Gene Therapy Product Development (Billion US$), 1999 to 2015
Figure 5-1: Global – Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
Figure 5-2: Global – Geographical Distribution of Gene Therapy Clinical Trials by Continents (%)
Figure 5-3: Global – Geographical Distribution of Gene Therapy Clinical Trials by Countries (%)
Figure 5-4: Global – Gene Therapy Clinical Trials by Indication (%)
Figure 5-5: Global – Gene Therapy Clinical Trials by Types of Gene Transferred (%)
Figure 5-6: Global – Gene Therapy Clinical Trials by Vectors (%)
Figure 5-7: Global – Gene Therapy Clinical Trials by Phase (%)
Figure 6-1: US – Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
Figure 6-2: Japan – Evaluation System of Gene Therapy Clinical Trial
Figure 7-1: Global – Neovasculgen Sales (Million US$), 2013 & 2014
Figure 8-1: Global – Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-1: Global – Gene Therapy Market by Application (%), 2015
Figure 9-2: Global – Gene Therapy Market by Application (%), 2020
Figure 9-3: Global – Oncology Gene Therapy Clinical Trials by Vectors (%)
Figure 9-4: Global – Oncology Gene Therapy Clinical Trials by Phase (%)
Figure 9-5: Global – Oncology Gene Therapy Clinical Trials by Type (%)
Figure 9-6: Global – Oncology Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-7: Global – Oncology Gene Therapy Market by Geography (%), 2015
Figure 9-8: Global – Key Cardiovascular Diseases Gene Therapy Ongoing Clinical Trials
Figure 9-9: Global – Cardiovascular Disease Gene Therapy Clinical Trials by Vectors (%)
Figure 9-10: Global – Cardiovascular Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-11: Global – Cardiovascular Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-12: Global – Cardiovascular Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-13: Global – Cardiovascular Disease Gene Therapy Market by Geography (%), 2015
Figure 9-14: Global – Infectious Disease Gene Therapy Clinical Trials by Vectors (%)
Figure 9-15: Global – Infectious Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-16: Global – Infectious Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-17: Global – Infectious Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-18: Global – Infectious Disease Gene Therapy Market by Geography (%), 2015
Figure 9-19: Global – Neurological Diseases Gene Therapy Clinical Trials by Vector (%)
Figure 9-20: Global – Neurological Diseases Gene Therapy Clinical Trials by Phase (%)
Figure 9-21: Global – Neurological Diseases Gene Therapy Clinical Trials by Type (%)
Figure 9-22: Global – Neurological Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-23: Global – Neurological Disease Gene Therapy Market by Geography (%), 2015
Figure 9-24: Global – Genetic Disease Gene Therapy Clinical Trials by Vector (%)
Figure 9-25: Global – Genetic Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-26: Global – Genetic Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-27: Global – Genetic Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-28: Global – Genetic Disease Gene Therapy Market, by Geography (%), 2015
Figure 9-29: Global – Other Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-30: Global – Other Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-31: Global – Other Disease Gene Therapy Market by Geography (%), 2015
Figure 10-1: Global – Gene Therapy Market by Geography (%), 2015
Figure 10-2: North America – Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-3: Europe – Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-4: Asia – Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-5: Asia – Number of Gene Therapy Laboratories by Major Asian Countries (2014)
Figure 10-6: India – Number of Gene Therapy Laboratories (2000, 2010 & 2013)
Figure 10-7: Rest of the World – Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

Table 4-1: US – Gene Therapies under Development
Table 4-2: Europe – Gene Therapies under Development
Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
Table 4-4: Current Status of Clinical Trials for Hemophilia
Table 5-1: Human Gene Transfer Trials Approved by Condition
Table 5-2: Global – Key Gene Therapy Ongoing Clinical Trials
Table 6-1: China – Key Players and their Products in Gene Therapy
Table 9-1: Global – Key Oncology Gene Therapy Ongoing Clinical Trials
Table 9-2: Global – Oncology Incidence by Geography (‘000), 2015 & 2020
Table 9-3: Global – Key Infectious Disease Gene Therapy Ongoing Clinical Trials
Table 9-4: Global – HIV Prevalence & Incidence by Geography (‘000), 2014
Table 9-5: Global – Key Neurological Disease Gene Therapy Ongoing Clinical Trials
Table 9-6: Global – Parkinson Disease Prevalence by Geography (Million), 2010
Table 9-7: Global – Key Genetic Disease Gene Therapy Ongoing Clinical Trials
Table 9-8: Global – Hemophilia Prevalence by Geography, 2010 & 2013
Table 9-9: Global – Key Other Disease Gene Therapy Ongoing Clinical Trials
Table 12-1: Spark Therapeutics LLC – Clinical Pipeline in Gene Therapy
Table 12-2: ViroMed Co. Ltd. – Clinical Pipeline in Gene Therapy
Table 12-3: Advantagene Inc. – Clinical Pipeline in Gene Therapy
Table 12-4: Bluebird Bio – Clinical Pipeline in Gene Therapy
Table 12-5: Sanofi – Clinical Pipeline in Gene Therapy
Table 12-6: Vical Inc. – Clinical Pipeline in Gene Therapy
Table 12-7: Oxford Biomedica Plc – Clinical Pipeline in Gene Therapy
Table 12-8: Genethon – Clinical Pipeline in Gene Therapy
Table 12-9: UniQure N.V. – Clinical Pipeline in Gene Therapy
Table 12-10: Human Stem Cells Institute – Clinical Pipeline in Gene Therapy
Table 12-11: Shanghai Sunway Biotech Co. Ltd. – Clinical Pipeline in Gene Therapy
Table 12-12: Sibiono GeneTech Co. Ltd. – Clinical Pipeline in Gene Therapy